Sanofi (NASDAQ:SNY) Hits New 52-Week High – Here’s What Happened

Sanofi (NASDAQ:SNY)’s share price reached a new 52-week high during trading on Tuesday . The stock traded as high as $60.12 and last traded at $59.35, with a volume of 3099845 shares changing hands. The stock had previously closed at $59.25.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $60.00.

Sanofi Price Performance

The company has a 50 day moving average of $52.87 and a 200-day moving average of $52.76. The stock has a market capitalization of $150.62 billion, a P/E ratio of 23.84, a PEG ratio of 1.01 and a beta of 0.58. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last issued its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sell-side analysts predict that Sanofi will post 4.36 EPS for the current year.

Institutional Investors Weigh In On Sanofi

Several large investors have recently added to or reduced their stakes in SNY. Price T Rowe Associates Inc. MD increased its position in Sanofi by 88.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company’s stock worth $522,991,000 after buying an additional 5,091,304 shares during the period. Raymond James Financial Inc. acquired a new stake in Sanofi in the fourth quarter worth $135,933,000. Boston Partners increased its position in Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company’s stock worth $260,607,000 after buying an additional 2,501,073 shares during the period. Jennison Associates LLC increased its position in Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after buying an additional 1,720,972 shares during the period. Finally, Magnetar Financial LLC increased its holdings in shares of Sanofi by 104.3% during the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock valued at $161,103,000 after purchasing an additional 1,705,148 shares during the period. 14.04% of the stock is owned by institutional investors and hedge funds.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.